Source: StemCells, Inc.
Date: November 15, 2010
Summary:
PALO ALTO, Calif., -- StemCells, Inc. announced today that is has filed an application with Swissmedic, the Swiss regulatory agency for therapeutic products, to conduct a clinical trial in Switzerland of the Company's HuCNS-SC(R) purified human neural stem cells in chronic spinal cord injury patients. If authorized, the study would enroll patients who are three to 12 months post-injury.
